Q4 2025 Genmab A/S Earnings Call Transcript
Key Points
- Genmab AS (GMAB) reported a 19% increase in total revenue for 2025, driven by both its royalty portfolio and sales from its own medicines.
- The company achieved significant milestones, including FDA approval for Abkinley in second-line follicular lymphoma, enhancing its potential as a core therapy in B cell lymphomas.
- Genmab AS (GMAB) expanded its development pipeline with three phase 3 trials for RAS across PO, endometrial cancer, and PSOC, indicating a strong commitment to growth in the gynecologic cancer space.
- The acquisition of Mirrors added Perentomab to Genmab AS (GMAB)'s portfolio, strengthening its late-stage assets and providing multiple value-creating catalysts for 2026.
- Genmab AS (GMAB) maintained a strong commercialization model, successfully executing four key launches and expanding its footprint to new markets, including Germany, the UK, and France.
- The phase 3 APC-DLBCL1 trial for Abkinley showed improvement in progression-free survival but did not reach statistical significance for overall survival, requiring further analysis.
- The company faces challenges with the impact of COVID-19 and the increasing availability of novel anti-lymphoma therapies, which may affect trial outcomes.
- Genmab AS (GMAB) anticipates significant investments in 2026 to advance late-stage development and support multiple potential product launches, which could impact short-term profitability.
- The company's guidance for 2026 reflects a 14% revenue growth, which is lower than the 19% growth achieved in 2025, indicating potential challenges in maintaining the same growth trajectory.
- There is uncertainty regarding the regulatory approval process for Abkinley, as discussions with health authorities are ongoing to address the confounded overall survival results in the EPCOR DLBC1 study.
Hello and welcome to the Gen map for year 2025 financial results conference call. As a reminder, this conference call is being recorded.
During this telephone conference, you may be presented with forward-looking statements that include words such as beliefs, anticipates, plans, or expects.
Actual results may differ materially, for example, as a result of delayed or unsuccessful development projects. Genmap is not under any obligation to update statements regarding the future, nor to confirm such statements in relation to actual results, unless this is required by law.
Please also note, GemMap may hold your personal data as indicated by you as a part of our investor relations outreach activities in order to update you on GMap going forward.
Please refer to our website for more information on G Map and our privacy policy.
I wouldn't allow to hand the conference over to our first speaker today, Jan van der Winkel. Please go ahead.
Hello and
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
